The Canadian Patent Office (CPO) is seeking comments on its proposed revisions to Chapter 17 of the Manual of Patent Office Practice (MOPOP) as it relates to pharmaceutical solid forms (namely, polymorphs, salts, hydrates, solvates, desolvates and co-crystals). In this …
Brazil Implements Patent Prosecution Highway with the United Kingdom – Opportunities for Biotechnology Applicants
On July 24, 2018, the Instituto Nacional da Propriedade Industrial (INPI) published Rule #222/2018 implementing the Patent Prosecution Highway (PPH) Pilot program (PPH program) with the United Kingdom patent and trademark Office (UKIPO). Implementation of this PPH program may expedite …
Tadalafil Patent Found Valid by Danish Maritime and Commercial High Court
Eli Lilly and Company (Eli Lilly) globally markets its product tadalafil (Cialis®) a PDE5 inhibitor, for use in the treatment of erectile (or sexual) dysfunction as well as for treating the signs and symptoms of benign prostatic hyperplasia. Tadalafil is …
Read More "Tadalafil Patent Found Valid by Danish Maritime and Commercial High Court"
USTR 2018 Special 301 Report – Priority Watch List Country – China
In April, the Office of the United States Trade Representative (USTR) released its 2018 Special 301 Report (the Report) identifying trading partners that do not adequately or effectively protect and enforce intellectual property (IP) rights or otherwise deny market access …
Read More "USTR 2018 Special 301 Report – Priority Watch List Country – China"
USTR 2018 Special 301 Report – Priority Watch List Country – India
In April, the Office of the United States Trade Representative (USTR) released its 2018 Special 301 Report (the Report) identifying trading partners that do not adequately or effectively protect and enforce intellectual property (IP) rights or otherwise deny market access …
Read More "USTR 2018 Special 301 Report – Priority Watch List Country – India"
USTR 2018 Special 301 Report: Pharmaceutical and Medical Device Innovation and Market Access
Last month, the Office of the United States Trade Representative (USTR) released its 2018 Special 301 Report (the Report), identifying trading partners that do not adequately or effectively protect and enforce intellectual property (IP) rights or otherwise deny market access …
Brazilian Mailbox Patents: Big Loss for Alexion
On April 20, 2018, Alexion Pharmaceutical Inc.’s (Alexion) patent (PI9507594-1) covering Soliris® (eculizumab) was the subject of an unfavorable decision by the Superior Court of Justice involving the term of mailbox patents in Brazil. Soliris® (eculizumab) is a humanized antibody …
